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Abstract
In light of waning immunity to pertussis following receipt of tetanus toxoid, reduced diphtheria 
toxoid and acellular pertussis (Tdap) vaccine, maintaining protection may require repeated Tdap 
vaccination. We evaluated the safety of repeated doses of tetanus-containing vaccine in 68 915 
nonpregnant adolescents and adults in the Vaccine Safety Datalink population who had received an 
initial dose of Tdap. Compared with 7521 subjects who received a subsequent dose of tetanus 
toxoid, reduced diphtheria (Td) vaccine, the 61 394 subjects who received a subsequent dose of 
Tdap did not have significantly elevated risk of medical visits for seizure, cranial nerve disorders, 
limb swelling, pain in limb, cellulitis, paralytic syndromes, or encephalopathy/encephalitis/
meningitis. These results suggest that repeated Tdap vaccination has acceptable safety relative to 
Tdap vaccination followed by Td vaccination.
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1 ∣ INTRODUCTION
The Advisory Committee on Immunization Practices recommends 1 dose of tetanus toxoid, 
reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine for adolescents aged 11 to 
18 years and for all adults aged ≥19 years not previously vaccinated.1,2 The Advisory 
Committee on Immunization Practices does not recommend repeated vaccination with Tdap 
except in pregnant women, who are recommended to receive Tdap during every pregnancy.3 
However, repeated Tdap vaccination may be necessary to maintain protection against 
pertussis, possibly with intervals of <10 years. Antibody concentrations to pertussis antigens 
wane to pre-Tdap levels within 10 years after Tdap vaccination,4 and vaccine effectiveness 
may wane within 5 years of Tdap receipt.5-7
Limited data are available regarding the safety of repeated Tdap vaccination. In adults and 
adolescents who had received Tdap as part of Tdap licensure trials, 4 studies did not find an 
elevated risk of local or systemic reactions to a second dose of Tdap, compared either with 
Tdap-naïve subjects or with subjects receiving a dose of tetanus toxoid and reduced 
diphtheria toxoid (Td) vaccine alone.4,8-10 However, these studies were small (between 82 
and 769 subjects) and unable to evaluate rare adverse events. A study of pregnant women 
found that women who received Tdap with an interval of <2 years since a prior dose of 
tetanus-containing vaccine did not have an elevated risk of medically attended local 
reactions relative to women with an interval of >5 years.11 Among nonpregnant adults and 
adolescents who received a first dose of Tdap, we assessed the safety of subsequent Tdap 
compared with subsequent Td, particularly at intervals <10 years between doses.
2 ∣ METHODS
2.1 ∣ Study population
We conducted a longitudinal cohort study within the Vaccine Safety Datalink (VSD), a 
collaboration between the Centers for Disease Control and Prevention and multiple managed 
care organizations (MCOs) in the United States.12 This study included 6 MCOs: Kaiser 
Permanente Washington, Kaiser Permanente Northwest, Kaiser Permanente Northern 
California, Kaiser Permanente Southern California, Kaiser Permanente Colorado, and the 
Marshfield Clinic. Managed care organization members were eligible to enter the study 
population when they met all the following criteria:
a. received a dose of Tdap between January 1, 2005 and December 31, 2014 on or 
after their 11th birthday but before their 65th birthday;
b. received a subsequent dose of any tetanus-containing vaccine between January 1, 
2005 and December 31, 2015 on or after their 11th birthday but before their 65th 
birthday; and
c. continuous enrollment in the MCO from 1 year prior to a dose of Tdap through a 
subsequent dose of any tetanus-containing vaccine.
Cohort members were followed for 42 days13 from the date of their second tetanus-
containing vaccine, or until they reached 65 years of age, disenrolled from the MCO, or 
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died, whichever came first. We did not assess risks after a third dose of tetanus-containing 
vaccine, as this was rarely observed. We excluded MCO enrollees if they were pregnant 
during their subsequent dose of tetanus-containing vaccine, as rates and detection of adverse 
events may differ during pregnancy than during other times.
2.2 ∣ Exposures of interest
We identified vaccine type and date of receipt of tetanus-containing vaccines by using 
immunization databases at each MCO. These databases include all vaccinations given to 
enrollees at each MCO. The immunization databases at Kaiser Permanente Washington, 
Marshfield Clinic, and Kaiser Permanente Northwest also exchange data with state 
immunization information systems, allowing us to identify initial Tdap vaccines received 
prior to MCO enrollment or outside the MCO health-care system.
2.3 ∣ Potential adverse events following vaccination
Consistent with a prior VSD study of Tdap safety,13 we considered 7 serious potential 
adverse events: seizure; cranial nerve disorders; limb swelling; pain in limb; cellulitis; 
paralytic syndromes; and encephalopathy, encephalitis, or meningitis. We did not include 
Guillain-Barré syndrome as an outcome,13,14 as preliminary analyses suggested that we 
would detect fewer than 5 Guillain-Barré syndrome cases in our population. We identified 
potential adverse events by using International Classification of Diseases, version 9, Clinical 
Modification (ICD-9-CM) codes assigned to inpatient, outpatient, and emergency 
department encounters (Table 1). For each subject, we identified first diagnosis date of each 
outcome occurring within the observation period after their second tetanus toxoid-containing 
vaccination. To exclude events which may have had onset prior to vaccination, we excluded 
any codes during the postvaccination observation period if those specific codes also occurred 
during the 30 days prior to vaccination.
2.4 ∣ Covariates of interest
We used enrollment and medical utilization databases at each MCO to define demographics, 
MCO enrollment history, indicators of healthcare utilization (numbers of outpatient visits, 
well care visits, and hospitalizations in the past year), and receipt of other recommended 
vaccinations. We defined these covariates as of the dates of initial Tdap and of second 
tetanus-containing vaccine.
2.5 ∣ Analysis
We compared covariate distributions between participants whose second dose of tetanus-
containing vaccine was Tdap vs Td. We estimated rates of potential adverse events, with 
95% CIs, assuming a Poisson distribution. To compare adverse event rates following Tdap 
vs Td as the second dose of tetanus-containing vaccine, we estimated rate ratios for each 
outcome of interest by using Poisson regression. A priori, models were adjusted for age at 
first receipt of Tdap, number of years between first Tdap and subsequent dose of tetanus-
containing vaccine, and year of second dose of tetanus-containing vaccine. We further 
included any covariates that altered the rate ratios from this base model by 10% or more. As 
secondary analyses, we stratified by time between vaccine doses (<3 years vs ≥3 years after 
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Tdap, the median interval between doses). Due to the smaller number of outcomes, these 
analyses were only adjusted for age at first Tdap, years between doses, and year of second 
dose. All analyses were conducted by using SAS version 9.4 (SAS Institute, Cary NC).
3 ∣ RESULTS
We identified 68 915 eligible VSD enrollees who received a dose of Tdap followed by a 
subsequent dose of tetanus-containing vaccine. Most (68%) received their first Tdap 
vaccination between 2006 and 2009. The median interval between vaccine doses was 2.9 
years (interquartile range, 1.3-5.2 years). Most study participants (89.1%) received a second 
dose of Tdap following their initial Tdap, with only 10.9% receiving Td as their next dose of 
tetanus-containing vaccine. Compared with participants who received a second Tdap, 
participants who received Td were more likely to be male, age ≥50 years, and have had ≥1 
well care visit in the prior year. Crude rates of potential adverse events after the second Tdap 
dose ranged from 0.8 cases per 10 000 vaccinees for encephalopathy/encephalitis/meningitis 
to 16.9 per 10 000 for pain in limb.
3.1 ∣ Primary analyses
Unadjusted adverse event rates were lower following a second dose of Tdap than following a 
subsequent Td for cellulitis (5.2 per 10 000 vaccinees after Tdap vs 5.3 after Td), limb 
swelling (3.4 vs 9.3 per 10 000), pain in limb (16.9 vs 33.2 per 10 000), and seizure (8.3 vs 
13.3 per 10 000). Cranial nerve disorders were slightly more common following Tdap (5.4 
per 10 000) compared with Td (4.0 per 10 000). In adjusted analyses, receipt of Tdap vs Td 
was not significantly associated with any of these outcomes (Figure 1). Only 6 cases of 
encephalopathy/encephalitis/meningitis were detected (5 following Tdap and 1 following 
Td), precluding adjusted analyses, but the crude rate ratio (0.6) was not statistically 
significant (95% confidence interval [CI], 0.1 to 5.2). Similarly, only 23 cases of paralytic 
syndromes were detected, with incidence of 2.9 per 10 000 vaccinees for Tdap and 6.6 per 
10 000 for Td (crude rate ratio 0.4, 95% CI, 0.2-1.2).
3.2 ∣ Stratified by time since first Tdap
Among subjects receiving a second dose of tetanus-containing vaccine <3 years after initial 
Tdap, receipt of Tdap vs Td was not significantly associated with any study outcome (Figure 
1). Among subjects receiving a second dose ≥3 years after initial Tdap, limb swelling and 
pain in limb were significantly less common among recipients of Tdap vs Td (Figure 1); 
significant associations were not observed for cellulitis, seizure, or cranial nerve disorders.
4 ∣ DISCUSSION
In light of waning immunity against pertussis following Tdap vaccination,5,6 a possible 
vaccination strategy would be to recommend Tdap in place of decennial Td doses. 
Information about the relative safety of Tdap vs Td following an initial dose of Tdap is 
needed to inform decisions regarding this strategy. This study suggests that a subsequent 
dose of Tdap is not associated with increased risks of potential adverse events, compared 
with a subsequent dose of Td. Specifically, we did not observe significantly elevated risks of 
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medical visits for cellulitis, limb swelling, pain in limb, seizure, cranial nerve disorders, 
paralytic syndromes, or encephalopathy/encephalitis/meningitis for Tdap relative to Td.
Several limitations of this study are worth considering. Outcomes of interest were defined by 
ICD-9-CM codes assigned to clinical encounters, excluding potential adverse events that did 
not result in an ambulatory care visit or hospitalization. International Classification of 
Diseases, version 9, Clinical Modification codes are also imperfectly sensitive and specific 
for the underlying medical outcomes, which may bias our risk ratio estimates. As with any 
observational study, our results may be subject to confounding due to unmeasured factors. 
Strengths include the use of population-based data with near-complete capture of 
vaccinations and medical encounters.
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FIGURE 1. 
Adjusted* rate ratios of adverse events following toxoid and acellular pertussis (Tdap) vs Td 
as a second dose of tetanus-containing vaccine following an initial dose of Tdap, overall and 
stratified by years between vaccine doses*Overall risk ratios adjusted for age at first Tdap, 
years between first Tdap and second tetanus-containing vaccine, sex, study site, receipt of 
human papillomavirus vaccine, and hospitalizations in the prior year. Stratified risk ratios 
adjusted for age at first Tdap and years between first Tdap and second tetanus-containing 
vaccine.
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